Fig. 4.

Systemic or intra-ACC MK-801 administration impairs 3-CSRT performance. MK-801 was administered either i.p. at doses of 0, 0.03, 0.1, or 0.3 mg/kg (a–d; n=8, 8, 8, and 3, respectively) or locally within the ACC at doses of 0, 1, or 3 μg/side (e–h n=15, 11, and 12, respectively). Performance was measured in terms of percent accuracy (a, e), percent omissions (b, f), premature responses (c, g), and total responses (d, h). Data are presented as mean±SEM. Asterisks indicate significant differences from vehicle (*p<0.05; **p<0.01)